CSI Market
Sign In | Register

Moleculin Biotech Inc (MBRX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access MBRX Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Moleculin Biotech Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-43.05
Depreciation & amortization0.02
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.82
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-10.76
Deferred Compensation Arrangement With Individual Compensation Expense-
Gain From Settlement Liability-
Common Stock Issued For License Rights Under License Agreement-
Loss On Issuance Of Warrant Liabilities15.16
Operating Lease Noncash Expense Net0.13
Common Stock Issued For Licence Rights Under License Agreement-
Income taxes0.00
Unrealized Gain (Loss) on Derivatives0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.83
Increase (Decrease) in Accrued Liabilities1.63
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.65
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities37.11
Discontinued operations0.00
Net Cash flow from Operating Activities-12.77
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.07
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.82
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net8.41
Proceeds from Issuance of Common Stock Net of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents8.88
Proceeds From Issuance Of Common Stock Prefunded Warrants And Common Warrants-
Proceeds From Transaction Costs Of Warrant Liabilities0.69
Proceeds From Sale Of Common Stock And Warrants Net Of Issuance Costs7.61
Proceeds From Sale Of Common Stock And Warrants Net Of Issuance And Transaction Costs And Warrant Inducement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities11.23
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-12.77
Total Cash Flow-1.62
4 historic quarters locked

Sign in to unlock the full Moleculin Biotech Inc cash flow history.

Sign In Create Free Account

About Moleculin Biotech Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-26-027688

Figures are derived from filed reports and may be restated. Historical data is subject to revision.